Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayes-Genis, Antoni, Iborra-Egea, Oriol, Spitaleri, Giosafat, Domingo, Mar, Revuelta-López, Elena, Codina, Pau, Cediel, Germán, Santiago-Vacas, Evelyn, Cserkóová, Adriana, Pascual-Figal, Domingo, Núñez, Julio, Lupón, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187349/
https://www.ncbi.nlm.nih.gov/pubmed/34103605
http://dx.doi.org/10.1038/s41598-021-91546-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187349/
https://www.ncbi.nlm.nih.gov/pubmed/34103605
http://dx.doi.org/10.1038/s41598-021-91546-z

Ejemplares similares